IA
TNXP icon

IFP Advisors’s Tonix Pharmaceuticals TNXP Stock Holding History

IFP Advisors’s Portfolio TNXP Stock Details TNXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.5K Buy
1,449
+93
+7% +$1.2K ﹤0.01% 3025
2026
Q1 		$18.6K Buy
1,356
+1,056
+352% +$16.3K ﹤0.01% 2816
2025
Q4 		$4.69K Buy
300
+100
+50% +$1.84K ﹤0.01% 3450
2025
Q3 		$4.83K Buy
+200
New +$7.42K ﹤0.01% 3269
2025
Q2 		– Sell
-10,000
Closed -$1.52K – 5015
2025
Q1 		$1.52K Buy
+10,000
New +$203K ﹤0.01% 3233
2024
Q1 		– Hold
0
– -$1 – 3239
2023
Q4 		– Hold
0
– – – 3037
2023
Q3 		– Hold
0
– – – 3287
2023
Q2 		– Hold
0
– – – 3434
2023
Q1 		– Hold
0
– – – 3347
2022
Q4 		– Hold
0
– – – 4487
2022
Q3 		– Hold
0
– – – 4416
2022
Q2 		– Hold
0
– – – 4195
2022
Q1 		– Hold
0
– – – 4193
2021
Q4 		– Hold
0
– – – 3127
2021
Q3 		– Hold
0
– – – 3139
2021
Q2 		– Hold
0
– – – 3237
2021
Q1 		– Hold
0
– – – 2883
2020
Q4 		– Hold
0
– – – 3094
2020
Q3 		– Hold
0
– – – 1913

Other funds holding TNXP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
II
Ishara Investments Los Angeles, California $136M AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

IFP Advisors's TNXP Position: Q2 2026 in Review

IFP Advisors increased its Tonix Pharmaceuticals (TNXP) stake by 6.9% in Q2 2026, buying an estimated $1.2K and bringing the position to 1,449 shares worth $18.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3025.

IFP Advisors first reported a position in TNXP in Q1 2025 and has held it in 5 quarters since. The position peaked at $18.6K in Q1 2026. 103 funds tracked by Wall St. Rank hold TNXP as of Q2 2026.

  • IFP Advisors held 1,449 shares of Tonix Pharmaceuticals worth $18.5K as of Q2 2026.
  • IFP Advisors bought 93 Tonix Pharmaceuticals shares in Q2 2026, an estimated $1.2K.
  • Tonix Pharmaceuticals made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #3025 holding.
  • IFP Advisors first reported a position in Tonix Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
  • IFP Advisors's Tonix Pharmaceuticals position peaked at $18.6K in Q1 2026.
  • 103 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.